The Relationship between Glaucoma Medication Adherence, Eye Drop Technique, and Visual Field Defect Severity

The purpose of the study was to examine (1) how patient adherence and eye drop technique were associated with visual field defect severity and (2) how general glaucoma adherence self-efficacy and eye drop technique self-efficacy were related to visual field defect severity. Cross-sectional study con...

Full description

Saved in:
Bibliographic Details
Published inOphthalmology (Rochester, Minn.) Vol. 118; no. 12; pp. 2398 - 2402
Main Authors Sleath, Betsy, Blalock, Susan, Covert, David, Stone, Jennifer L., Skinner, Asheley Cockrell, Muir, Kelly, Robin, Alan L.
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 01.12.2011
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The purpose of the study was to examine (1) how patient adherence and eye drop technique were associated with visual field defect severity and (2) how general glaucoma adherence self-efficacy and eye drop technique self-efficacy were related to visual field defect severity. Cross-sectional study conducted at a single private practice site. Patients using eye drops for their glaucoma. Subject adherence to glaucoma medications through Medication Events Monitoring System (MEMS) devices were measured, and eye drop instillation technique was assessed by video recording. General glaucoma medication adherence self-efficacy was measured using a 10-item scale, and eye drop technique self-efficacy was measured using a 6-item scale. Multivariate logistic regression was used to analyze the data. Visual field defect severity. Patients who were less than 80% adherent according to the MEMS devices were significantly more likely to have worse defect severity. Patients with lower scores on the general glaucoma medication adherence self-efficacy scale also were significantly more likely to have worse defect severity. Eye drop technique and eye drop technique self-efficacy were not related significantly to visual field defect severity. Eye care providers need to assess patient adherence and to work with those patients with poor adherence to find ways to improve their ability and self-efficacy in using their glaucoma medications. Proprietary or commercial disclosure may be found after the references.
AbstractList The purpose of the study was to examine (1) how patient adherence and eye drop technique were associated with visual field defect severity and (2) how general glaucoma adherence self-efficacy and eye drop technique self-efficacy were related to visual field defect severity. Cross-sectional study conducted at a single private practice site. Patients using eye drops for their glaucoma. Subject adherence to glaucoma medications through Medication Events Monitoring System (MEMS) devices were measured, and eye drop instillation technique was assessed by video recording. General glaucoma medication adherence self-efficacy was measured using a 10-item scale, and eye drop technique self-efficacy was measured using a 6-item scale. Multivariate logistic regression was used to analyze the data. Visual field defect severity. Patients who were less than 80% adherent according to the MEMS devices were significantly more likely to have worse defect severity. Patients with lower scores on the general glaucoma medication adherence self-efficacy scale also were significantly more likely to have worse defect severity. Eye drop technique and eye drop technique self-efficacy were not related significantly to visual field defect severity. Eye care providers need to assess patient adherence and to work with those patients with poor adherence to find ways to improve their ability and self-efficacy in using their glaucoma medications. Proprietary or commercial disclosure may be found after the references.
Objective The purpose of the study was to examine (1) how patient adherence and eye drop technique were associated with visual field defect severity and (2) how general glaucoma adherence self-efficacy and eye drop technique self-efficacy were related to visual field defect severity. Design Cross-sectional study conducted at a single private practice site. Participants Patients using eye drops for their glaucoma. Methods Subject adherence to glaucoma medications through Medication Events Monitoring System (MEMS) devices were measured, and eye drop instillation technique was assessed by video recording. General glaucoma medication adherence self-efficacy was measured using a 10-item scale, and eye drop technique self-efficacy was measured using a 6-item scale. Multivariate logistic regression was used to analyze the data. Main Outcome Measures Visual field defect severity. Results Patients who were less than 80% adherent according to the MEMS devices were significantly more likely to have worse defect severity. Patients with lower scores on the general glaucoma medication adherence self-efficacy scale also were significantly more likely to have worse defect severity. Eye drop technique and eye drop technique self-efficacy were not related significantly to visual field defect severity. Conclusions Eye care providers need to assess patient adherence and to work with those patients with poor adherence to find ways to improve their ability and self-efficacy in using their glaucoma medications. Financial Disclosure(s) Proprietary or commercial disclosure may be found after the references.
The purpose of the study was to examine (1) how patient adherence and eye drop technique were associated with visual field defect severity and (2) how general glaucoma adherence self-efficacy and eye drop technique self-efficacy were related to visual field defect severity.OBJECTIVEThe purpose of the study was to examine (1) how patient adherence and eye drop technique were associated with visual field defect severity and (2) how general glaucoma adherence self-efficacy and eye drop technique self-efficacy were related to visual field defect severity.Cross-sectional study conducted at a single private practice site.DESIGNCross-sectional study conducted at a single private practice site.Patients using eye drops for their glaucoma.PARTICIPANTSPatients using eye drops for their glaucoma.Subject adherence to glaucoma medications through Medication Events Monitoring System (MEMS) devices were measured, and eye drop instillation technique was assessed by video recording. General glaucoma medication adherence self-efficacy was measured using a 10-item scale, and eye drop technique self-efficacy was measured using a 6-item scale. Multivariate logistic regression was used to analyze the data.METHODSSubject adherence to glaucoma medications through Medication Events Monitoring System (MEMS) devices were measured, and eye drop instillation technique was assessed by video recording. General glaucoma medication adherence self-efficacy was measured using a 10-item scale, and eye drop technique self-efficacy was measured using a 6-item scale. Multivariate logistic regression was used to analyze the data.Visual field defect severity.MAIN OUTCOME MEASURESVisual field defect severity.Patients who were less than 80% adherent according to the MEMS devices were significantly more likely to have worse defect severity. Patients with lower scores on the general glaucoma medication adherence self-efficacy scale also were significantly more likely to have worse defect severity. Eye drop technique and eye drop technique self-efficacy were not related significantly to visual field defect severity.RESULTSPatients who were less than 80% adherent according to the MEMS devices were significantly more likely to have worse defect severity. Patients with lower scores on the general glaucoma medication adherence self-efficacy scale also were significantly more likely to have worse defect severity. Eye drop technique and eye drop technique self-efficacy were not related significantly to visual field defect severity.Eye care providers need to assess patient adherence and to work with those patients with poor adherence to find ways to improve their ability and self-efficacy in using their glaucoma medications.CONCLUSIONSEye care providers need to assess patient adherence and to work with those patients with poor adherence to find ways to improve their ability and self-efficacy in using their glaucoma medications.Proprietary or commercial disclosure may be found after the references.FINANCIAL DISCLOSURE(S)Proprietary or commercial disclosure may be found after the references.
Author Stone, Jennifer L.
Covert, David
Muir, Kelly
Robin, Alan L.
Skinner, Asheley Cockrell
Blalock, Susan
Sleath, Betsy
AuthorAffiliation 2 Department of Health Economics, Alcon Research Ltd. Fort Worth, Texas
6 Department of International Health, Bloomberg School of Public Health; Department of Ophthalmology, School of Medicine; Johns Hopkins University and University of Maryland School of Medicine, Baltimore, Maryland
5 Department of Ophthalmology; School of Medicine, Duke University
3 Mid-Atlantic Glaucoma Experts, Baltimore, Maryland
4 Department of Pediatrics; Health Policy and Management; University of North Carolina at Chapel Hill
1 Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill
AuthorAffiliation_xml – name: 5 Department of Ophthalmology; School of Medicine, Duke University
– name: 1 Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill
– name: 6 Department of International Health, Bloomberg School of Public Health; Department of Ophthalmology, School of Medicine; Johns Hopkins University and University of Maryland School of Medicine, Baltimore, Maryland
– name: 3 Mid-Atlantic Glaucoma Experts, Baltimore, Maryland
– name: 2 Department of Health Economics, Alcon Research Ltd. Fort Worth, Texas
– name: 4 Department of Pediatrics; Health Policy and Management; University of North Carolina at Chapel Hill
Author_xml – sequence: 1
  givenname: Betsy
  surname: Sleath
  fullname: Sleath, Betsy
  email: betsy_sleath@unc.edu
  organization: Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
– sequence: 2
  givenname: Susan
  surname: Blalock
  fullname: Blalock, Susan
  organization: Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
– sequence: 3
  givenname: David
  surname: Covert
  fullname: Covert, David
  organization: Department of Health Economics, Alcon Research Ltd., Fort Worth, Texas
– sequence: 4
  givenname: Jennifer L.
  surname: Stone
  fullname: Stone, Jennifer L.
  organization: Mid-Atlantic Glaucoma Specialists, Baltimore, Maryland
– sequence: 5
  givenname: Asheley Cockrell
  surname: Skinner
  fullname: Skinner, Asheley Cockrell
  organization: Department of Pediatrics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
– sequence: 6
  givenname: Kelly
  surname: Muir
  fullname: Muir, Kelly
  organization: Department of Ophthalmology, School of Medicine, Duke University, Durham, North Carolina
– sequence: 7
  givenname: Alan L.
  surname: Robin
  fullname: Robin, Alan L.
  organization: Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, and Department of Ophthalmology, School of Medicine, University of Maryland School of Medicine, Baltimore, Maryland
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25286153$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/21856009$$D View this record in MEDLINE/PubMed
BookMark eNqVkl1rFDEUhoNU7Lb6D0RyI964azLJTGalCKVfChXBrt6GTHLGyZpN1mRmZf-9me5aP0CKV4HkOe8h5zlH6MAHDwg9pWRGCa1eLWdh3fWdmhWE0hkpZ4SyB2hCSz6fckHZAZpkjE4rXpBDdJTSkhBSVYw_QocFrcuKkPkEuUUH-CM41dvgU2fXuIH-O4DHV04NOqwUfg_G6tt3fGo6iOA1vMQXW8DnMazxAnTn7bch3ylv8GebBuXwpQVn8Dm0oHt8AxuItt8-Rg9b5RI82Z_H6NPlxeLs7fT6w9W7s9Prqa4K0k-FoUI0LafQGkLN3GhTN6pVDddG6JoKSoFVhJG6actWlKJgTdU0tWa60aVR7Bi92eWuh2YFRoPvo3JyHe1Kxa0Myso_X7zt5JewkawoWMnrHPBiHxBD_lnq5comDc4pD2FIck5qwangIpPPfm911-PnhDPwfA-opJVro_Lapl9cWdQVLVnm-I7TMaQUob1DKJGjcLmUO-FyFC5JKbPwXPb6rzJt-1tZ-WPW3Ve8nxNkGRsLUSZtR73GxuxNmmD_N0A76_O2uK-whbQMQ_RZtKQyFZLIm3Ehx32klBBeVuOgT_4dcH__H3S78_g
CODEN OPHTDG
CitedBy_id crossref_primary_10_1186_s12886_016_0220_6
crossref_primary_10_1080_17469899_2024_2382149
crossref_primary_10_1167_tvst_8_3_55
crossref_primary_10_1097_IJG_0000000000001728
crossref_primary_10_1007_s12325_023_02646_3
crossref_primary_10_1186_s12886_022_02361_7
crossref_primary_10_1001_jamaophthalmol_2021_4415
crossref_primary_10_1136_bmjophth_2017_000114
crossref_primary_10_2147_PPA_S239916
crossref_primary_10_1016_j_pec_2018_12_019
crossref_primary_10_1038_s41433_022_02277_y
crossref_primary_10_1016_j_ogla_2023_07_002
crossref_primary_10_1038_s41433_023_02693_8
crossref_primary_10_1097_IJG_0000000000001965
crossref_primary_10_1097_OPX_0000000000000574
crossref_primary_10_5005_jp_journals_10008_1183
crossref_primary_10_1016_j_jfma_2018_07_011
crossref_primary_10_1089_jop_2012_0241
crossref_primary_10_1007_s00441_013_1672_0
crossref_primary_10_1146_annurev_vision_102016_061422
crossref_primary_10_1089_jop_2018_0067
crossref_primary_10_1021_acsbiomaterials_7b00319
crossref_primary_10_3390_jcm12093137
crossref_primary_10_1016_j_jfo_2016_02_004
crossref_primary_10_1007_s10792_022_02460_w
crossref_primary_10_1097_IJG_0000000000002368
crossref_primary_10_2147_OPTH_S439457
crossref_primary_10_1016_j_ogla_2021_07_012
crossref_primary_10_1177_11206721241272179
crossref_primary_10_1097_ICU_0000000000000927
crossref_primary_10_1136_bjophthalmol_2021_320023
crossref_primary_10_1097_IJG_0000000000001716
crossref_primary_10_1080_17469899_2023_2199981
crossref_primary_10_5402_2012_902819
crossref_primary_10_3341_jkos_2023_64_1_43
crossref_primary_10_1007_s40123_019_0192_8
crossref_primary_10_3109_09273948_2014_902473
crossref_primary_10_4103_ijo_IJO_3333_20
crossref_primary_10_1080_17425255_2017_1277203
crossref_primary_10_1016_j_ophtha_2020_11_004
crossref_primary_10_2147_OPTH_S450220
crossref_primary_10_1186_1471_2415_12_57
crossref_primary_10_1177_2515841418812061
crossref_primary_10_1080_07853890_2021_1955146
crossref_primary_10_5005_jp_journals_10078_1283
crossref_primary_10_1016_j_ophtha_2019_04_034
crossref_primary_10_1007_s00417_021_05091_6
crossref_primary_10_1097_IJG_0000000000001982
crossref_primary_10_2147_OPTH_S420932
crossref_primary_10_1038_eye_2012_294
crossref_primary_10_1097_IJG_0000000000000777
crossref_primary_10_4103_jcsr_jcsr_174_23
crossref_primary_10_1007_s10597_016_0078_3
crossref_primary_10_1016_j_xops_2025_100706
crossref_primary_10_1016_j_ophtha_2024_03_012
crossref_primary_10_1097_IJG_0000000000001867
crossref_primary_10_1016_j_ogla_2022_08_001
crossref_primary_10_1111_aos_14776
crossref_primary_10_3341_jkos_2021_62_8_1105
crossref_primary_10_1007_s40265_019_01248_0
crossref_primary_10_1016_j_aopr_2024_09_002
crossref_primary_10_3390_app13137562
crossref_primary_10_3390_jcm5090079
crossref_primary_10_1016_j_xops_2024_100541
crossref_primary_10_3389_fopht_2023_1260415
crossref_primary_10_1016_j_ophtha_2016_06_038
crossref_primary_10_1016_j_ajo_2013_03_005
crossref_primary_10_1016_j_ogla_2021_04_007
crossref_primary_10_1111_ceo_13016
crossref_primary_10_1016_j_jfo_2022_07_025
crossref_primary_10_1007_s40123_021_00380_z
crossref_primary_10_1371_journal_pone_0145764
crossref_primary_10_1186_s12951_023_01838_x
crossref_primary_10_1097_IJG_0000000000001731
crossref_primary_10_1155_2017_1683430
crossref_primary_10_1016_j_ogla_2019_01_006
crossref_primary_10_2147_OPTH_S498431
crossref_primary_10_1016_j_jconrel_2017_11_008
crossref_primary_10_1016_j_clinthera_2015_06_008
crossref_primary_10_1016_j_ogla_2021_06_001
crossref_primary_10_1097_ICU_0000000000000031
crossref_primary_10_1371_journal_pone_0251699
crossref_primary_10_1016_j_ajo_2016_12_002
crossref_primary_10_1016_j_ophtha_2015_04_019
crossref_primary_10_1097_ICU_0000000000000953
crossref_primary_10_1097_IJG_0000000000000150
crossref_primary_10_1016_j_ajo_2020_09_008
crossref_primary_10_1016_j_ajo_2020_10_004
crossref_primary_10_1016_j_ajo_2024_12_015
crossref_primary_10_1021_acsomega_4c08540
crossref_primary_10_1080_09286586_2019_1708121
crossref_primary_10_1097_IJG_0000000000002213
crossref_primary_10_1038_eye_2013_187
crossref_primary_10_1089_jop_2015_0102
crossref_primary_10_3109_08820538_2013_771198
crossref_primary_10_3390_jcm13010184
crossref_primary_10_1016_j_ogla_2024_12_002
crossref_primary_10_1111_ceo_13156
crossref_primary_10_2147_OPTH_S445005
crossref_primary_10_1016_j_jcrs_2014_02_037
crossref_primary_10_1089_jop_2024_0029
crossref_primary_10_1016_j_ophtha_2015_06_039
crossref_primary_10_1007_s40123_022_00527_6
crossref_primary_10_1089_jop_2019_0146
crossref_primary_10_1016_j_ajo_2015_12_009
crossref_primary_10_3109_02713683_2013_855237
crossref_primary_10_1007_s40265_024_02074_9
crossref_primary_10_1097_IJG_0000000000002324
crossref_primary_10_2147_OPTH_S325763
crossref_primary_10_1097_APO_0000000000000023
crossref_primary_10_1097_APO_0000000000000025
crossref_primary_10_1016_j_preteyeres_2019_100801
crossref_primary_10_1093_her_cyv034
crossref_primary_10_1186_s40814_018_0320_6
crossref_primary_10_1016_j_ogla_2024_01_008
crossref_primary_10_1016_j_ogla_2020_04_013
crossref_primary_10_1016_j_ophtha_2012_11_026
crossref_primary_10_4103_tmj_tmj_16_23
crossref_primary_10_1016_j_ogla_2020_04_016
crossref_primary_10_1016_j_ajo_2018_01_011
crossref_primary_10_1155_2016_9183272
crossref_primary_10_3390_jcm12010151
crossref_primary_10_1177_1060028014529413
crossref_primary_10_1097_IJG_0000000000001943
crossref_primary_10_1097_OPX_0000000000001366
crossref_primary_10_2147_OPTH_S278627
crossref_primary_10_1016_j_ajo_2022_08_011
crossref_primary_10_1080_14656566_2020_1795130
crossref_primary_10_1097_IJG_0000000000001824
crossref_primary_10_1136_bmjophth_2023_001607
crossref_primary_10_1016_j_ijpharm_2019_01_070
crossref_primary_10_1016_j_evalprogplan_2017_06_006
crossref_primary_10_1016_j_biomaterials_2013_09_032
crossref_primary_10_1186_s12886_016_0316_z
crossref_primary_10_1177_2515841419863638
crossref_primary_10_1016_j_ogla_2024_12_008
crossref_primary_10_1016_j_ogla_2020_08_003
crossref_primary_10_1007_s40135_021_00273_1
crossref_primary_10_1080_08820538_2021_1985145
crossref_primary_10_1016_j_ogla_2023_04_004
crossref_primary_10_23736_S0026_4946_16_04731_9
crossref_primary_10_1007_s10792_021_02085_5
crossref_primary_10_1080_00981389_2019_1614711
crossref_primary_10_5005_jp_journals_10008_1139
crossref_primary_10_1097_IJG_0000000000002343
crossref_primary_10_1097_IJG_0000000000002228
crossref_primary_10_3390_s20092570
crossref_primary_10_1016_j_clae_2015_02_001
crossref_primary_10_1007_s40123_024_01041_7
crossref_primary_10_1016_j_ogla_2023_05_001
crossref_primary_10_1038_s41433_020_0798_z
crossref_primary_10_1155_joph_9803788
crossref_primary_10_3390_ijms242115599
crossref_primary_10_2147_OPTH_S335764
crossref_primary_10_1016_j_ajo_2020_01_004
crossref_primary_10_18553_jmcp_2018_17465
crossref_primary_10_15275_rusomj_2022_0407
crossref_primary_10_1016_j_exer_2022_109006
crossref_primary_10_1097_OPX_0000000000000856
crossref_primary_10_3390_jcm12083031
crossref_primary_10_1155_2023_5625990
crossref_primary_10_2147_OPTH_S321351
crossref_primary_10_1080_14740338_2020_1826928
crossref_primary_10_1080_10410236_2015_1020263
crossref_primary_10_3109_02713683_2014_1002045
crossref_primary_10_1016_j_ophtha_2013_01_002
crossref_primary_10_2147_OPTH_S440840
crossref_primary_10_1007_s40123_023_00804_y
crossref_primary_10_3390_healthcare11050635
crossref_primary_10_1016_j_ogla_2024_11_003
crossref_primary_10_1016_j_pec_2015_07_001
crossref_primary_10_1185_03007995_2013_815159
crossref_primary_10_54133_ajms_v7i2_1283
crossref_primary_10_1016_j_ophtha_2014_11_001
crossref_primary_10_1097_j_jcrs_0000000000001537
crossref_primary_10_1177_25158414211045751
crossref_primary_10_3389_fmed_2022_867884
crossref_primary_10_1016_j_jconrel_2015_06_035
crossref_primary_10_1016_j_jaapos_2024_103963
crossref_primary_10_1371_journal_pone_0316835
crossref_primary_10_1089_tmj_2016_0254
crossref_primary_10_1097_IJG_0000000000000342
crossref_primary_10_1097_IJG_0000000000000345
crossref_primary_10_1016_j_ogla_2025_01_008
crossref_primary_10_7759_cureus_15545
crossref_primary_10_1016_j_ogla_2023_01_006
crossref_primary_10_1089_jop_2015_0052
crossref_primary_10_1080_17434440_2018_1419060
crossref_primary_10_21516_2072_0076_2024_17_2_121_127
crossref_primary_10_1080_02713683_2019_1625405
crossref_primary_10_3390_gels8080510
crossref_primary_10_1186_1471_2415_14_79
crossref_primary_10_1136_bjophthalmol_2021_319786
crossref_primary_10_1097_IJG_0000000000000380
crossref_primary_10_1038_s41433_023_02674_x
crossref_primary_10_53394_akd_1057689
crossref_primary_10_1016_j_ophtha_2019_10_022
crossref_primary_10_1038_s41433_019_0665_y
crossref_primary_10_1080_03007995_2024_2322048
crossref_primary_10_1080_13696998_2019_1646262
crossref_primary_10_1038_s41598_017_15954_w
crossref_primary_10_1371_journal_pone_0293047
crossref_primary_10_1097_ICU_0000000000001077
crossref_primary_10_1111_cxo_12372
crossref_primary_10_1089_tmj_2017_0324
crossref_primary_10_1007_s40265_023_01973_7
crossref_primary_10_3390_ijms24065636
crossref_primary_10_1038_s41551_020_00645_1
crossref_primary_10_1097_OPX_0000000000001959
crossref_primary_10_2147_PPA_S264926
crossref_primary_10_1111_ijpp_12215
crossref_primary_10_18502_jovr_v19i2_13983
crossref_primary_10_1111_vop_13029
crossref_primary_10_1001_jamaophthalmol_2022_0055
crossref_primary_10_1159_000512924
crossref_primary_10_1007_s00347_012_2641_9
crossref_primary_10_1007_s40123_023_00831_9
crossref_primary_10_3390_app15031627
crossref_primary_10_1080_03007995_2024_2323644
crossref_primary_10_1016_j_yaoo_2021_04_011
crossref_primary_10_1016_j_ogla_2023_06_002
crossref_primary_10_1007_s12160_014_9641_8
crossref_primary_10_1002_14651858_CD010520_pub2
crossref_primary_10_1016_j_ajo_2020_02_009
crossref_primary_10_1097_ICU_0000000000000555
crossref_primary_10_1016_j_jcjo_2021_01_008
crossref_primary_10_1097_IJG_0000000000000431
crossref_primary_10_1007_s40265_021_01624_9
crossref_primary_10_1016_j_ophtha_2016_04_026
crossref_primary_10_1097_OPX_0000000000001173
crossref_primary_10_1007_s40266_015_0282_9
crossref_primary_10_1016_j_jcrs_2018_07_015
crossref_primary_10_1097_IJG_0000000000002166
crossref_primary_10_1371_journal_pone_0312390
crossref_primary_10_1155_2015_234157
crossref_primary_10_1097_j_jcrs_0000000000000363
crossref_primary_10_1139_cjc_2017_0193
crossref_primary_10_1089_jop_2013_0229
crossref_primary_10_1136_bjophthalmol_2020_317918
crossref_primary_10_3390_pharmaceutics16070933
crossref_primary_10_1097_ICU_0000000000000451
crossref_primary_10_1186_1471_2415_14_32
crossref_primary_10_1016_j_ophtha_2020_06_018
crossref_primary_10_1080_09286586_2022_2078495
crossref_primary_10_1007_s00441_013_1637_3
crossref_primary_10_1097_IJG_0000000000000332
crossref_primary_10_4103_IJO_IJO_2186_23
crossref_primary_10_18553_jmcp_2016_22_7_808
crossref_primary_10_1016_j_pec_2023_107679
crossref_primary_10_1080_10410236_2014_888387
crossref_primary_10_1007_s40123_019_00214_z
crossref_primary_10_1016_j_jcjo_2014_04_012
crossref_primary_10_1016_j_ajo_2016_11_020
crossref_primary_10_1177_25158414241287431
crossref_primary_10_1016_j_ajo_2015_03_006
crossref_primary_10_1016_j_ajo_2017_07_023
crossref_primary_10_1097_IIO_0000000000000441
crossref_primary_10_2147_OPTH_S452159
crossref_primary_10_18553_jmcp_2019_25_9_1001
crossref_primary_10_1097_IJG_0000000000001891
crossref_primary_10_1016_j_ogla_2022_09_003
crossref_primary_10_1097_IJG_0000000000000320
crossref_primary_10_1136_bmjopen_2020_039788
crossref_primary_10_1016_j_xops_2025_100758
crossref_primary_10_1016_j_ophtha_2015_03_026
crossref_primary_10_1007_s40123_024_01087_7
crossref_primary_10_1080_17469899_2019_1635456
crossref_primary_10_1177_17407745221136571
Cites_doi 10.1016/j.ophtha.2008.09.004
10.1016/j.amjopharm.2009.04.001
10.1038/eye.2000.197
10.1136/bjo.64.2.137
10.1016/j.ophtha.2005.10.034
10.1136/bjo.87.5.648
10.1016/j.ophtha.2004.12.035
10.1016/j.ophtha.2009.01.021
10.1097/00061198-200310000-00001
10.1001/archophthalmol.2009.96
10.1097/00005650-199808000-00004
10.1016/S0002-9394(14)74225-4
10.1016/j.ajo.2010.05.005
10.1016/j.ajo.2006.03.018
10.1038/eye.2009.174
10.1016/j.ophtha.2004.12.026
10.1097/IJG.0b013e31819c4679
10.1345/aph.1K671
10.1016/j.ajo.2007.06.012
10.1089/10807680260362687
10.1097/01.mlr.0000114908.90348.f9
ContentType Journal Article
Copyright 2011 American Academy of Ophthalmology
American Academy of Ophthalmology
2015 INIST-CNRS
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
2011 American Academy of Ophthalmology, Inc. Published by Elsevier Inc. All rights reserved. 2011
Copyright_xml – notice: 2011 American Academy of Ophthalmology
– notice: American Academy of Ophthalmology
– notice: 2015 INIST-CNRS
– notice: Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
– notice: 2011 American Academy of Ophthalmology, Inc. Published by Elsevier Inc. All rights reserved. 2011
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1016/j.ophtha.2011.05.013
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1549-4713
EndPage 2402
ExternalDocumentID PMC3223548
21856009
25286153
10_1016_j_ophtha_2011_05_013
S0161642011004568
1_s2_0_S0161642011004568
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: National Institutes of Health
  grantid: EY018400
– fundername: National Center of Research Resources, National Institutes of Health
  grantid: 1RR02574 7
– fundername: NCRR NIH HHS
  grantid: UL1RR02574 7
– fundername: NEI NIH HHS
  grantid: EY018400
– fundername: NEI NIH HHS
  grantid: R01 EY018400
– fundername: National Eye Institute : NEI
  grantid: R01 EY018400-03 || EY
GroupedDBID ---
--K
.1-
.55
.FO
.GJ
0R~
123
1B1
1CY
1P~
1~5
29N
4.4
457
4G.
53G
5RE
5VS
7-5
71M
AAEDT
AAEDW
AALRI
AAQFI
AAQQT
AAQXK
AAXUO
ABCQX
ABFRF
ABJNI
ABLJU
ABMAC
ABOCM
ABWVN
ACGFO
ACGFS
ACIUM
ACNCT
ACRPL
ACVFH
ADCNI
ADMUD
ADNMO
AEFWE
AENEX
AEUPX
AEVXI
AFFNX
AFJKZ
AFPUW
AFRHN
AFTJW
AGCQF
AGQPQ
AIGII
AITUG
AJUYK
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BELOY
C5W
CS3
DU5
EBS
EFJIC
EFKBS
EJD
F5P
FDB
FEDTE
FGOYB
GBLVA
HVGLF
HZ~
IHE
J1W
K-O
KOM
L7B
M27
M41
MO0
N4W
N9A
NQ-
O9-
OF-
OPF
OQ~
P2P
R2-
ROL
RPZ
SDG
SEL
SES
SSZ
UHS
UNMZH
UV1
WH7
X7M
XH2
XPP
Z5R
ZGI
ZXP
ADPAM
RIG
AAIAV
AGZHU
AHPSJ
ALXNB
ZA5
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c620t-7d177bf41efd01d9dcd8bafab4cd7c81711e360308bf5f75723b6bb8c3cbc5da3
ISSN 0161-6420
1549-4713
IngestDate Thu Aug 21 18:27:28 EDT 2025
Fri Jul 11 00:46:19 EDT 2025
Sat May 31 02:07:38 EDT 2025
Mon Jul 21 09:10:50 EDT 2025
Thu Apr 24 23:08:15 EDT 2025
Tue Jul 01 01:01:32 EDT 2025
Fri Feb 23 02:14:12 EST 2024
Sun Feb 23 10:19:56 EST 2025
Tue Aug 26 19:02:59 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords Eye drop
Drug
Eye disease
Chemotherapy
Treatment
Visual field disease
Glaucoma (eye)
Visual field defect
Ophthalmology
Technique
Adhesion
Language English
License CC BY 4.0
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c620t-7d177bf41efd01d9dcd8bafab4cd7c81711e360308bf5f75723b6bb8c3cbc5da3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 21856009
PQID 908741747
PQPubID 23479
PageCount 5
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3223548
proquest_miscellaneous_908741747
pubmed_primary_21856009
pascalfrancis_primary_25286153
crossref_primary_10_1016_j_ophtha_2011_05_013
crossref_citationtrail_10_1016_j_ophtha_2011_05_013
elsevier_sciencedirect_doi_10_1016_j_ophtha_2011_05_013
elsevier_clinicalkeyesjournals_1_s2_0_S0161642011004568
elsevier_clinicalkey_doi_10_1016_j_ophtha_2011_05_013
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2011-12-01
PublicationDateYYYYMMDD 2011-12-01
PublicationDate_xml – month: 12
  year: 2011
  text: 2011-12-01
  day: 01
PublicationDecade 2010
PublicationPlace New York, NY
PublicationPlace_xml – name: New York, NY
– name: United States
PublicationTitle Ophthalmology (Rochester, Minn.)
PublicationTitleAlternate Ophthalmology
PublicationYear 2011
Publisher Elsevier Inc
Elsevier
Publisher_xml – name: Elsevier Inc
– name: Elsevier
References Tsai, McClure, Ramos (bib13) 2003; 12
Meichenbaum, Turk (bib15) 1987
Konstas, Maskaleris, Gratsonidis, Sardelli (bib19) 2000; 14
Robin, Covert (bib12) 2005; 112
Stryker, Beck, Primo (bib6) 2010; 19
Hodapp, Parrish, Anderson (bib26) 1993
Martin, Wiley-Exley, Richards (bib27) 2009; 41
Friedman, Okeke, Jampel (bib21) 2009; 116
Robin, Novack, Covert (bib11) 2007; 144
Stone, Robin, Novack (bib23) 2009; 127
Patel, Spaeth (bib28) 1995; 26
DiMatteo (bib17) 2004; 42
Sleath, Robin, Covert (bib9) 2006; 113
Sleath, Ballinger, Covert (bib7) 2009; 7
Taylor, Galbraith, Mills (bib14) 2002; 18
Spaeth (bib1) 1970; 9
Olthoff, Schouten, van de Borne, Webers (bib18) 2005; 112
Okeke, Quigley, Jampel (bib4) 2009; 116
Lu, Goldberg, Lu (bib5) 2010; 150
Rossi, Pasinetti, Scudeller (bib22) 2010 Dec 3
Kass, Hodapp, Gordon (bib3) 1982; 14
Sleath, Blalock, Robin (bib8) 2010; 24
Kass, Gordon, Morley (bib24) 1987; 103
Roter, Hall, Merisca (bib16) 1998; 36
Chen, Chao, Sorkin (bib20) 2003; 87
Sleath, Blalock, Stone (bib25) 2011 May 24
Muir, Santiago-Turla, Stinnett (bib10) 2006; 142
Norell, Granstrom (bib2) 1980; 64
Sleath (10.1016/j.ophtha.2011.05.013_bib8) 2010; 24
Stryker (10.1016/j.ophtha.2011.05.013_bib6) 2010; 19
Muir (10.1016/j.ophtha.2011.05.013_bib10) 2006; 142
Sleath (10.1016/j.ophtha.2011.05.013_bib7) 2009; 7
Patel (10.1016/j.ophtha.2011.05.013_bib28) 1995; 26
Lu (10.1016/j.ophtha.2011.05.013_bib5) 2010; 150
Robin (10.1016/j.ophtha.2011.05.013_bib11) 2007; 144
Robin (10.1016/j.ophtha.2011.05.013_bib12) 2005; 112
Spaeth (10.1016/j.ophtha.2011.05.013_bib1) 1970; 9
DiMatteo (10.1016/j.ophtha.2011.05.013_bib17) 2004; 42
Chen (10.1016/j.ophtha.2011.05.013_bib20) 2003; 87
Sleath (10.1016/j.ophtha.2011.05.013_bib9) 2006; 113
Friedman (10.1016/j.ophtha.2011.05.013_bib21) 2009; 116
Tsai (10.1016/j.ophtha.2011.05.013_bib13) 2003; 12
Taylor (10.1016/j.ophtha.2011.05.013_bib14) 2002; 18
Stone (10.1016/j.ophtha.2011.05.013_bib23) 2009; 127
Kass (10.1016/j.ophtha.2011.05.013_bib24) 1987; 103
Kass (10.1016/j.ophtha.2011.05.013_bib3) 1982; 14
Roter (10.1016/j.ophtha.2011.05.013_bib16) 1998; 36
Okeke (10.1016/j.ophtha.2011.05.013_bib4) 2009; 116
Olthoff (10.1016/j.ophtha.2011.05.013_bib18) 2005; 112
Konstas (10.1016/j.ophtha.2011.05.013_bib19) 2000; 14
Meichenbaum (10.1016/j.ophtha.2011.05.013_bib15) 1987
Martin (10.1016/j.ophtha.2011.05.013_bib27) 2009; 41
Hodapp (10.1016/j.ophtha.2011.05.013_bib26) 1993
Norell (10.1016/j.ophtha.2011.05.013_bib2) 1980; 64
Rossi (10.1016/j.ophtha.2011.05.013_bib22) 2010
Sleath (10.1016/j.ophtha.2011.05.013_bib25) 2011
References_xml – volume: 142
  start-page: 223
  year: 2006
  end-page: 226
  ident: bib10
  article-title: Health literacy and adherence to glaucoma therapy
  publication-title: Am J Ophthalmol
– volume: 12
  start-page: 393
  year: 2003
  end-page: 398
  ident: bib13
  article-title: Compliance barriers in glaucoma: a systematic classification
  publication-title: J Glaucoma
– volume: 103
  start-page: 188
  year: 1987
  end-page: 193
  ident: bib24
  article-title: Compliance with topical timolol treatment
  publication-title: Am J Ophthalmol
– start-page: 1
  year: 1987
  end-page: 55
  ident: bib15
  article-title: Facilitating Treatment Adherence
  publication-title: A Practitioner's Guidebook
– volume: 9
  start-page: 73
  year: 1970
  end-page: 82
  ident: bib1
  article-title: Visual loss in a glaucoma clinic. I. Sociological considerations
  publication-title: Invest Ophthalmol
– volume: 26
  start-page: 233
  year: 1995
  end-page: 236
  ident: bib28
  article-title: Compliance in patients prescribed eye drops for glaucoma
  publication-title: Ophthalmic Surg
– volume: 7
  start-page: 67
  year: 2009
  end-page: 73
  ident: bib7
  article-title: Self-report prevalence and factors associated with nonadherence with glaucoma medications in veteran outpatients
  publication-title: Am J Geriatr Pharmacother
– volume: 42
  start-page: 200
  year: 2004
  end-page: 209
  ident: bib17
  article-title: Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research
  publication-title: Med Care
– volume: 14
  start-page: 752
  year: 2000
  end-page: 756
  ident: bib19
  article-title: Compliance and viewpoint of glaucoma patients in Greece
  publication-title: Eye (Lond)
– volume: 64
  start-page: 137
  year: 1980
  end-page: 141
  ident: bib2
  article-title: Self-medication with pilocarpine among outpatients in a glaucoma clinic
  publication-title: Br J Ophthalmol
– volume: 19
  start-page: 66
  year: 2010
  end-page: 72
  ident: bib6
  article-title: An exploratory study of factors influencing glaucoma treatment adherence
  publication-title: J Glaucoma
– volume: 112
  start-page: 863
  year: 2005
  end-page: 868
  ident: bib12
  article-title: Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?
  publication-title: Ophthalmology
– start-page: 53
  year: 1993
  end-page: 59
  ident: bib26
  article-title: Clinical Decisions in Glaucoma
– volume: 116
  start-page: 191
  year: 2009
  end-page: 199
  ident: bib4
  article-title: Adherence with topical glaucoma medication monitored electronically: the Travatan Dosing Aid study
  publication-title: Ophthalmology
– year: 2011 May 24
  ident: bib25
  article-title: Validation of a short version of the Glaucoma Medication Self-Efficacy Questionnaire
  publication-title: Br J Ophthalmol
– volume: 150
  start-page: 569
  year: 2010
  end-page: 574
  ident: bib5
  article-title: Use of glaucoma medications: state of the science and directions for observational research
  publication-title: Am J Ophthalmol
– volume: 112
  start-page: 953
  year: 2005
  end-page: 961
  ident: bib18
  article-title: Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review
  publication-title: Ophthalmology
– volume: 144
  start-page: 533
  year: 2007
  end-page: 540
  ident: bib11
  article-title: Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use
  publication-title: Am J Ophthalmol
– year: 2010 Dec 3
  ident: bib22
  article-title: Do adherence rates and glaucomatous visual field progression correlate?
  publication-title: Eur J Ophthalmol
– volume: 87
  start-page: 648
  year: 2003
  end-page: 649
  ident: bib20
  article-title: Topiramate induced myopic shift and angle closure glaucoma [letter]
  publication-title: Br J Ophthalmol
– volume: 18
  start-page: 401
  year: 2002
  end-page: 409
  ident: bib14
  article-title: Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study
  publication-title: J Ocul Pharmacol Ther
– volume: 116
  start-page: 1097
  year: 2009
  end-page: 1105
  ident: bib21
  article-title: Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma
  publication-title: Ophthalmology
– volume: 24
  start-page: 624
  year: 2010
  end-page: 631
  ident: bib8
  article-title: Development of an instrument to measure glaucoma medication self-efficacy and outcome expectations
  publication-title: Eye (Lond)
– volume: 113
  start-page: 421
  year: 2006
  end-page: 426
  ident: bib9
  article-title: Patient-reported behavior and problems in using glaucoma medications
  publication-title: Ophthalmology
– volume: 36
  start-page: 1138
  year: 1998
  end-page: 1161
  ident: bib16
  article-title: Effectiveness of interventions to improve patient compliance: a meta-analysis
  publication-title: Med Care
– volume: 14
  start-page: 775
  year: 1982
  end-page: 779
  ident: bib3
  article-title: Part I. Patient administration of eyedrops: interview
  publication-title: Ann Ophthalmol
– volume: 127
  start-page: 732
  year: 2009
  end-page: 736
  ident: bib23
  article-title: An objective evaluation of eyedrop instillation in subjects with glaucoma
  publication-title: Arch Ophthalmol
– volume: 41
  start-page: 36
  year: 2009
  end-page: 44
  ident: bib27
  article-title: Contrasting measures of adherence in the presence of simple drug use, medication switching, and therapeutic duplication
  publication-title: Ann Pharmacother
– volume: 116
  start-page: 191
  year: 2009
  ident: 10.1016/j.ophtha.2011.05.013_bib4
  article-title: Adherence with topical glaucoma medication monitored electronically: the Travatan Dosing Aid study
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2008.09.004
– volume: 7
  start-page: 67
  year: 2009
  ident: 10.1016/j.ophtha.2011.05.013_bib7
  article-title: Self-report prevalence and factors associated with nonadherence with glaucoma medications in veteran outpatients
  publication-title: Am J Geriatr Pharmacother
  doi: 10.1016/j.amjopharm.2009.04.001
– volume: 14
  start-page: 752
  year: 2000
  ident: 10.1016/j.ophtha.2011.05.013_bib19
  article-title: Compliance and viewpoint of glaucoma patients in Greece
  publication-title: Eye (Lond)
  doi: 10.1038/eye.2000.197
– volume: 64
  start-page: 137
  year: 1980
  ident: 10.1016/j.ophtha.2011.05.013_bib2
  article-title: Self-medication with pilocarpine among outpatients in a glaucoma clinic
  publication-title: Br J Ophthalmol
  doi: 10.1136/bjo.64.2.137
– volume: 113
  start-page: 421
  year: 2006
  ident: 10.1016/j.ophtha.2011.05.013_bib9
  article-title: Patient-reported behavior and problems in using glaucoma medications
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2005.10.034
– volume: 87
  start-page: 648
  year: 2003
  ident: 10.1016/j.ophtha.2011.05.013_bib20
  article-title: Topiramate induced myopic shift and angle closure glaucoma [letter]
  publication-title: Br J Ophthalmol
  doi: 10.1136/bjo.87.5.648
– start-page: 53
  year: 1993
  ident: 10.1016/j.ophtha.2011.05.013_bib26
  article-title: Clinical Decisions in Glaucoma
– volume: 14
  start-page: 775
  year: 1982
  ident: 10.1016/j.ophtha.2011.05.013_bib3
  article-title: Part I. Patient administration of eyedrops: interview
  publication-title: Ann Ophthalmol
– volume: 112
  start-page: 953
  year: 2005
  ident: 10.1016/j.ophtha.2011.05.013_bib18
  article-title: Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2004.12.035
– volume: 116
  start-page: 1097
  year: 2009
  ident: 10.1016/j.ophtha.2011.05.013_bib21
  article-title: Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2009.01.021
– volume: 12
  start-page: 393
  year: 2003
  ident: 10.1016/j.ophtha.2011.05.013_bib13
  article-title: Compliance barriers in glaucoma: a systematic classification
  publication-title: J Glaucoma
  doi: 10.1097/00061198-200310000-00001
– volume: 127
  start-page: 732
  year: 2009
  ident: 10.1016/j.ophtha.2011.05.013_bib23
  article-title: An objective evaluation of eyedrop instillation in subjects with glaucoma
  publication-title: Arch Ophthalmol
  doi: 10.1001/archophthalmol.2009.96
– volume: 9
  start-page: 73
  year: 1970
  ident: 10.1016/j.ophtha.2011.05.013_bib1
  article-title: Visual loss in a glaucoma clinic. I. Sociological considerations
  publication-title: Invest Ophthalmol
– volume: 36
  start-page: 1138
  year: 1998
  ident: 10.1016/j.ophtha.2011.05.013_bib16
  article-title: Effectiveness of interventions to improve patient compliance: a meta-analysis
  publication-title: Med Care
  doi: 10.1097/00005650-199808000-00004
– volume: 103
  start-page: 188
  year: 1987
  ident: 10.1016/j.ophtha.2011.05.013_bib24
  article-title: Compliance with topical timolol treatment
  publication-title: Am J Ophthalmol
  doi: 10.1016/S0002-9394(14)74225-4
– volume: 150
  start-page: 569
  year: 2010
  ident: 10.1016/j.ophtha.2011.05.013_bib5
  article-title: Use of glaucoma medications: state of the science and directions for observational research
  publication-title: Am J Ophthalmol
  doi: 10.1016/j.ajo.2010.05.005
– volume: 142
  start-page: 223
  year: 2006
  ident: 10.1016/j.ophtha.2011.05.013_bib10
  article-title: Health literacy and adherence to glaucoma therapy
  publication-title: Am J Ophthalmol
  doi: 10.1016/j.ajo.2006.03.018
– volume: 24
  start-page: 624
  year: 2010
  ident: 10.1016/j.ophtha.2011.05.013_bib8
  article-title: Development of an instrument to measure glaucoma medication self-efficacy and outcome expectations
  publication-title: Eye (Lond)
  doi: 10.1038/eye.2009.174
– volume: 26
  start-page: 233
  year: 1995
  ident: 10.1016/j.ophtha.2011.05.013_bib28
  article-title: Compliance in patients prescribed eye drops for glaucoma
  publication-title: Ophthalmic Surg
– year: 2010
  ident: 10.1016/j.ophtha.2011.05.013_bib22
  article-title: Do adherence rates and glaucomatous visual field progression correlate?
  publication-title: Eur J Ophthalmol
– year: 2011
  ident: 10.1016/j.ophtha.2011.05.013_bib25
  article-title: Validation of a short version of the Glaucoma Medication Self-Efficacy Questionnaire
  publication-title: Br J Ophthalmol
– volume: 112
  start-page: 863
  year: 2005
  ident: 10.1016/j.ophtha.2011.05.013_bib12
  article-title: Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2004.12.026
– volume: 19
  start-page: 66
  year: 2010
  ident: 10.1016/j.ophtha.2011.05.013_bib6
  article-title: An exploratory study of factors influencing glaucoma treatment adherence
  publication-title: J Glaucoma
  doi: 10.1097/IJG.0b013e31819c4679
– volume: 41
  start-page: 36
  year: 2009
  ident: 10.1016/j.ophtha.2011.05.013_bib27
  article-title: Contrasting measures of adherence in the presence of simple drug use, medication switching, and therapeutic duplication
  publication-title: Ann Pharmacother
  doi: 10.1345/aph.1K671
– volume: 144
  start-page: 533
  year: 2007
  ident: 10.1016/j.ophtha.2011.05.013_bib11
  article-title: Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use
  publication-title: Am J Ophthalmol
  doi: 10.1016/j.ajo.2007.06.012
– start-page: 1
  year: 1987
  ident: 10.1016/j.ophtha.2011.05.013_bib15
  article-title: Facilitating Treatment Adherence
– volume: 18
  start-page: 401
  year: 2002
  ident: 10.1016/j.ophtha.2011.05.013_bib14
  article-title: Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study
  publication-title: J Ocul Pharmacol Ther
  doi: 10.1089/10807680260362687
– volume: 42
  start-page: 200
  year: 2004
  ident: 10.1016/j.ophtha.2011.05.013_bib17
  article-title: Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research
  publication-title: Med Care
  doi: 10.1097/01.mlr.0000114908.90348.f9
SSID ssj0006634
Score 2.5106504
Snippet The purpose of the study was to examine (1) how patient adherence and eye drop technique were associated with visual field defect severity and (2) how general...
Objective The purpose of the study was to examine (1) how patient adherence and eye drop technique were associated with visual field defect severity and (2)...
SourceID pubmedcentral
proquest
pubmed
pascalfrancis
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2398
SubjectTerms Administration, Ophthalmic
Adult
Aged
Aged, 80 and over
Antihypertensive Agents - administration & dosage
Biological and medical sciences
Cross-Sectional Studies
Diseases of visual field, optic nerve, optic chiasma and optic tracts
Female
Glaucoma - drug therapy
Glaucoma - ethnology
Glaucoma and intraocular pressure
Humans
Male
Medical sciences
Medication Adherence
Middle Aged
Miscellaneous
Ophthalmic Solutions - administration & dosage
Ophthalmology
Self Administration
Severity of Illness Index
Surveys and Questionnaires
Treatment Outcome
Vision Disorders - physiopathology
Visual Acuity - physiology
Visual Field Tests
Visual Fields - physiology
Title The Relationship between Glaucoma Medication Adherence, Eye Drop Technique, and Visual Field Defect Severity
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0161642011004568
https://www.clinicalkey.es/playcontent/1-s2.0-S0161642011004568
https://dx.doi.org/10.1016/j.ophtha.2011.05.013
https://www.ncbi.nlm.nih.gov/pubmed/21856009
https://www.proquest.com/docview/908741747
https://pubmed.ncbi.nlm.nih.gov/PMC3223548
Volume 118
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZKJyEkhLiOcpn8wNuWKnEudh6rwZgYA4ltsDcrthO1U0irJX2A38KP5Th2blvRxl6iKo1r1-fL8Tn2d85B6B0ThMZulDixBBUYuFngCFe4jpCBkkyJgCgdnHz8JTo8Cz6dh-ej0Z8ea2ldian8vTGu5C5ShXsgVx0l-x-SbX8UbsBnkC9cQcJwvbWMWzZbn3X1MU_W0GFiz2FqGc_U3IT21ervV7r7_nK5MlvrOodrQ-P8vih1RMmBZraBNqpzG5-kMDWLanAC_HU1r-ZJ_tPkcKo3ImztLcPGL4ppb5fhJNemZg2mtCq7IIo8ya1CHtCD9jWxtLrCua9rupkN2IaTs_t52t-20Ly5AQWkjacZ0D21_emAR-QO9HOnoNct6dqqW9-UsLZLtz4p2rgsmB2Ki-mynhqbuFXna_W7ZbAlJ57oUehB1Nn0wojdQ1sEnBAyRluzo28_jtqVHqw1mzvejLoJzaz5g9f7-pfp83CVlPBCZqaSyiZX5ypjt2cCnT5Gj6zvgmcGiE_QKC2eovvHlp3xDOWAR9zHI7Z4xA0ecYdH3OJxDwMasUYjbtG4hwGL2GAR11jEBou4weJzdHbw4XT_0LHVPBwZEbdyqPIoFVngpZlyPRUrqZhIskQEUlHJPOp5qR_p9EkiCzMaUuKLSAgmfSlkqBL_BRoXgLKXCIcxcWOWpr4pj-AxJSMGhmhGPclCIibIbyaaS5vqXldcyXnDabzgRjxci4e7IQfxTJDTtlqZVC83PB82MuRNGDMsvBxAd0M7uqldWlrNUnKPl4S7_BoQ-y2tgWwM31v0uTMAWfsHSUiY9vkmCDeo47DA6FPDpEiX65LHLgOvgwZ0grYNCLvGYOyDwxTDuAbwbB_QueuH3xSLeZ3DHuwIPwzYqzvO4Wv0oFMqb9C4ulynb8E7qMSOfUn_AiXvEgE
linkProvider Library Specific Holdings
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Relationship+between+Glaucoma+Medication+Adherence%2C+Eye+Drop+Technique%2C+and+Visual+Field+Defect+Severity&rft.jtitle=Ophthalmology+%28Rochester%2C+Minn.%29&rft.au=Sleath%2C+Betsy&rft.au=Blalock%2C+Susan&rft.au=Covert%2C+David&rft.au=Stone%2C+Jennifer+L.&rft.date=2011-12-01&rft.pub=Elsevier+Inc&rft.issn=0161-6420&rft.volume=118&rft.issue=12&rft.spage=2398&rft.epage=2402&rft_id=info:doi/10.1016%2Fj.ophtha.2011.05.013&rft.externalDocID=S0161642011004568
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01616420%2FS0161642011X00118%2Fcov150h.gif